Original Literature | Model OverView |
---|---|
Publication
Title
IRAK-4--a shared NF-kappaB activator in innate and acquired immunity.
Affiliation
Laboratory for Cell Signaling, RIKEN Research Center for Allergy and Immunology,1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama 230-0045, Japan. nobu@rcai.riken.jp
Abstract
The human body is protected against external pathogens by two immune systems:innate and acquired immunities. Whereas innate immunity exhibits immediateresponses to external pathogens by recognizing pathogen-associated molecularpatterns (PAMPs), adaptive immunity uses T cells to recognize and defend againstpathogens by developing effector cells, antibodies and memory cells. Althougheach system seems to possess distinct activation mechanisms, interleukin-1receptor-associated kinase (IRAK)-4 is essential for NF-kappaB activation inToll-like receptor (TLR) and T-cell receptor (TCR) signaling pathways. Thisimplies possible crosstalk between innate and acquired immunities, andevolutionary development that resulted in the use of innate signaling moleculesby the acquired immune system. Here, we discuss the impact of theseevolutionarily conserved molecules on innate and acquired immunity, and theirpotential as drug targets for the simultaneous modulation of both immunities.
PMID
17046325
|
Entity
Process
IFN-beta
--
G010228
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m93217
10
infinite
0
TRANSFAC | G010228 |
--
IL-6
--
G010262
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m93248
10
infinite
0
TRANSFAC | G010262 |
--
TNF-alpha
--
G010329
cso30:c:mRNA
cso30:i:CC_CellComponent
--
csml-variable:Double
m93309
10
infinite
0
TRANSFAC | G010329 |
--
IFN-gamma
--
G010453
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m93423
10
infinite
0
TRANSFAC | G010453 |
--
NF-kappaB {activated}
--
MO000000058
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6
10
infinite
0
TRANSPATH | MO000000058 |
--
TRAF6
--
MO000000212
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m183
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000000212 |
--
IRAK-1
--
MO000000213
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m184
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000000213 |
--
IL-1
--
MO000000214
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m185
10
infinite
0
TRANSPATH | MO000000214 |
--
chemokines
--
MO000000265
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m211
10
infinite
0
TRANSPATH | MO000000265 |
--
TNF-alpha
--
MO000000289
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m230
10
infinite
0
InterPro | IPR003636 |
TRANSPATH | MO000000289 |
--
IL-6
--
MO000007384
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m871
10
infinite
0
InterPro | IPR003573 |
TRANSPATH | MO000007384 |
--
IRF-5
--
MO000007700
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m979
10
infinite
0
InterPro | IPR008984 |
TRANSPATH | MO000007700 |
--
IRF-7
--
MO000007702
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m980
10
infinite
0
TRANSPATH | MO000007702 |
--
MyD88
--
MO000016573
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1572
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000016573 |
--
IFNbeta
--
MO000016660
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1636
10
infinite
0
InterPro | IPR000471 |
TRANSPATH | MO000016660 |
--
IFNgamma
--
MO000016665
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1639
10
infinite
0
InterPro | IPR002069 |
TRANSPATH | MO000016665 |
--
calcineurin
--
MO000016724
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m1676
10
infinite
0
TRANSPATH | MO000016724 |
--
TRAF3
--
MO000016963
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m1872
10
infinite
0
InterPro | IPR001841 |
TRANSPATH | MO000016963 |
--
Bcl-xL
--
MO000017151
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2028
10
infinite
0
InterPro | IPR004725 |
TRANSPATH | MO000017151 |
--
IL-10
--
MO000017247
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2103
10
infinite
0
InterPro | IPR000098 |
TRANSPATH | MO000017247 |
--
IL-8
--
MO000017264
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2120
10
infinite
0
InterPro | IPR002473 |
TRANSPATH | MO000017264 |
--
PKCtheta
--
MO000017433
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2259
10
infinite
0
InterPro | IPR000719 |
TRANSPATH | MO000017433 |
--
PLCgamma1
--
MO000017617
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m2395
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000017617 |
--
PLCgamma2
--
MO000017704
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m2464
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000017704 |
--
cytokines
--
MO000019387
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m3957
10
infinite
0
TRANSPATH | MO000019387 |
--
csml-variable:Double
m6433
10
infinite
0
--
flagellin
--
MO000022185
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m6485
10
infinite
0
TRANSPATH | MO000022185 |
--
TIRAP
--
MO000022528
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m6810
10
infinite
0
InterPro | IPR000157 |
TRANSPATH | MO000022528 |
--
IRAK-4
--
MO000039077
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m17258
10
infinite
0
TRANSPATH | MO000039077 |
--
--
e1
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane
--
--
--
csml-variable:Double
m1
0
infinite
0
--
--
e10
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytosol
--
--
--
csml-variable:Double
m10
0
infinite
0
--
Ca
--
e100
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
csml-variable:Double
m104
0
infinite
0
--
cyclosporine
--
e101
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m105
0
infinite
0
--
FK506
--
e102
cso30:c:SmallMolecule
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m106
0
infinite
0
--
IkappaB: NFkappaB
--
e103
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m107
0
infinite
0
--
Triacyl lipopeptide
--
e104
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m108
0
infinite
0
--
Diacyl lipopeptide
--
e105
cso30:c:SmallMolecule
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m109
0
infinite
0
--
IkappaB {p}: NFkappaB
--
e106
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m110
0
infinite
0
--
IkappaB {ub}: NFkappaB
--
e107
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m111
0
infinite
0
--
--
e11
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeLumen
--
--
--
csml-variable:Double
m12
0
infinite
0
--
--
e12
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Endosome
--
--
--
csml-variable:Double
m13
0
infinite
0
--
Uev1A
--
e13
cso30:c:Protein
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m14
0
infinite
0
--
TLR ligand
--
e14
cso30:c:Protein
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m16
0
infinite
0
--
TLR ligand: TLR
--
e15
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m17
0
infinite
0
--
TLR ligand: TLR: MyD88
--
e16
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m18
0
infinite
0
--
IL1
--
e17
cso30:c:mRNA
cso30:i:CC_CellComponent
--
csml-variable:Double
m19
10
infinite
0
TRANSFAC | G011140 |
--
csml-variable:Double
m22
0
infinite
0
--
--
e2
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m2
0
infinite
0
--
TLR2: TLR1: Triacyl lipopeptide
--
e21
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m25
0
infinite
0
--
TLR2: TLR6: Diacyl lipopeptide
--
e22
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m26
0
infinite
0
--
TLR2: TLR6: Diacyl lipopeptide: TIRAP
--
e23
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m27
0
infinite
0
--
TLR2: TLR1: Triacyl lipopeptide: TIRAP
--
e24
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m28
0
infinite
0
--
TLR2: TLR1: Triacyl lipopeptide: TIRAP: MyD88
--
e25
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m29
0
infinite
0
--
TLR2: TLR6:Diacyl lipopeptide: TIRAP: MyD88
--
e26
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m30
0
infinite
0
--
csml-variable:Double
m31
0
infinite
0
--
R-848: TLR7
--
e28
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m32
0
infinite
0
--
R-848: TLR8
--
e29
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m33
0
infinite
0
--
--
e3
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
--
csml-variable:Double
m3
0
infinite
0
--
CpG DNA: TLR9
--
e30
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m34
0
infinite
0
--
flagellin: TLR5
--
e31
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m35
0
infinite
0
--
csml-variable:Double
m36
10
infinite
0
Affymetrix | 1369_s_at |
Ensembl | ENSG00000169429 |
HGNC | IL8 |
OMIM | 146930 |
Proteome | HumanPSD/IL8 |
RefSeq | NM_000584 |
TRANSFAC | G000317 |
Unigene | Hs.551925 |
--
flagellin: TLR5: MyD88
--
e33
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m37
0
infinite
0
--
R-848: TLR7: MyD88
--
e34
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m38
0
infinite
0
--
R-848: TLR8: MyD88
--
e35
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m39
0
infinite
0
--
CpG DNA: TLR9: MyD88
--
e36
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m40
0
infinite
0
--
R-848: TLR8: MyD88: IRAK-1: IRAK-4: TRAF6: TRAF3: IRF-5: IRF-7
--
e37
cso30:c:Complex
cso30:i:CC_EndosomeLumen
--
csml-variable:Double
m41
0
infinite
0
--
R-848: TLR7: MyD88: IRAK-1: IRAK-4: TRAF6: TRAF3: IRF-5: IRF-7
--
e38
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m42
0
infinite
0
--
CpG DNA: TLR9: MyD88: IRAK-1: IRAK-4: TRAF6: TRAF3: IRF-5: IRF-7
--
e39
cso30:c:Complex
cso30:i:CC_EndosomeMembrane
--
csml-variable:Double
m43
0
infinite
0
--
--
e4
cso30:c:EntityBiologicalCompartment
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
--
--
csml-variable:Double
m4
0
infinite
0
--
LPS: TLR4
--
e40
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m44
0
infinite
0
--
LPS: TLR4: TIRAP
--
e41
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m45
0
infinite
0
--
LPS: TLR4: TRAM
--
e42
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m46
0
infinite
0
--
LPS: TLR4: TIRAP: MyD88
--
e43
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m47
0
infinite
0
--
LPS: TLR4: TRAM: TRIF
--
e44
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m48
0
infinite
0
--
LPS: TLR4: TRAM: TRIF: RIP1
--
e45
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m49
0
infinite
0
--
poly I:C: TLR3
--
e46
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_InternalSideOfPlasmaMembrane_
--
csml-variable:Double
m63
0
infinite
0
--
poly I:C: TLR3: TRIF
--
e47
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m64
0
infinite
0
--
csml-variable:Double
m65
0
infinite
0
--
poly I:C: TLR3: TRIF: RIP1
--
e49
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m66
0
infinite
0
--
IKK-alpha:IKK-beta:IKK-gamma
--
e5
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m5
10
infinite
0
TRANSPATH | MO000016661 |
--
--
e50
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelopeLumen
--
--
--
csml-variable:Double
m50
0
infinite
0
--
--
e51
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearPore
--
--
--
csml-variable:Double
m51
0
infinite
0
--
--
e52
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearInnerMembrane
--
--
--
csml-variable:Double
m52
0
infinite
0
--
--
e53
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearLumen
--
--
--
csml-variable:Double
m53
0
infinite
0
--
--
e54
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearOuterMembrane
--
--
--
csml-variable:Double
m54
0
infinite
0
--
--
e55
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleus
--
--
--
csml-variable:Double
m55
0
infinite
0
--
--
e56
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleoplasm
--
--
--
csml-variable:Double
m56
0
infinite
0
--
--
e57
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearBody
--
--
--
csml-variable:Double
m57
0
infinite
0
--
--
e58
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Nucleolus
--
--
--
csml-variable:Double
m58
0
infinite
0
--
--
e59
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearEnvelope
--
--
--
csml-variable:Double
m59
0
infinite
0
--
--
e6
cso30:c:EntityBiologicalCompartment
cso30:i:CC_EndosomeMembrane
--
--
--
csml-variable:Double
m11
0
infinite
0
--
--
e60
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Chromatin
--
--
--
csml-variable:Double
m60
0
infinite
0
--
--
e61
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearChromosome
--
--
--
csml-variable:Double
m61
0
infinite
0
--
--
e62
cso30:c:EntityBiologicalCompartment
cso30:i:CC_NuclearCentromere
--
--
--
csml-variable:Double
m62
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-1: IRAK-4: TRAF6: IRF-5
--
e63
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m67
0
infinite
0
--
IRAK-1{p}: TRAF6
--
e64
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m68
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-1{p}: IRAK-4: TRAF6: IRF-5
--
e65
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m70
0
infinite
0
--
TLR ligand: TLR: MyD88: IRAK-4: IRF-5
--
e66
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m71
0
infinite
0
--
IRAK-1{p}: TRAF6: TAK1: TAB1: TAB2: Ubc13: Uev1A
--
e67
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m72
0
infinite
0
--
IRAK-1{p}: TRAF6: TAK1 {activated}: TAB1: TAB2: Ubc13: Uev1A
--
e68
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m73
0
infinite
0
--
IKK-alpha:IKK-beta:IKK-gamma {p}
--
e69
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m74
0
infinite
0
--
--
e7
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell
--
--
--
csml-variable:Double
m7
0
infinite
0
--
MAPKs {activated}
--
e72
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m20
10
infinite
0
TRANSPATH | MO000000077 |
--
protein ramnents
--
e74
cso30:c:EntityBiological
cso30:i:CC_Cytosol
--
csml-variable:Double
m78
0
infinite
0
--
NF-kappaB {nucleus}
--
e75
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m79
10
infinite
0
TRANSPATH | MO000000058 |
--
TLR ligand: TLR: MyD88: IRAK-1: IRAK-4: TRAF6: IRF-5 {activated}
--
e76
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m80
0
infinite
0
--
IFNalpha
--
e77
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m81
10
infinite
0
InterPro | IPR000471 |
TRANSPATH | MO000016659 |
--
antigen-MHC complex
--
e78
cso30:c:Complex
cso30:i:CC_Extracellular
--
--
csml-variable:Double
m82
0
infinite
0
--
IFNalpha
--
e79
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m83
10
infinite
0
TRANSFAC | G010227 |
--
--
e8
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cell_WithoutCellWall_
--
--
--
csml-variable:Double
m8
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta
--
e80
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m84
0
infinite
0
--
TCR: CD3zeta
--
e81
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
csml-variable:Double
m85
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta {p}
--
e82
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m86
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta {p}: ZAP-70
--
e83
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
csml-variable:Double
m87
0
infinite
0
--
LAT: SLP-76
--
e84
cso30:c:Complex
cso30:i:CC_Cytosol
--
--
csml-variable:Double
m88
0
infinite
0
--
LAT {p}: SLP-76 {p}
--
e85
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m89
0
infinite
0
--
LAT {p}: SLP-76 {p}: PLCgamma1
--
e86
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m90
0
infinite
0
--
PKCtheta {p}
--
e87
cso30:c:Protein
cso30:i:CC_Cytosol
--
csml-variable:Double
m91
0
infinite
0
--
antigen-MHC complex: TCR: CD3zeta {p}: ZAP-70: IRAK-4
--
e88
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m92
0
infinite
0
--
calcineurin {activated}
--
e89
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m93
10
infinite
0
TRANSPATH | MO000016724 |
--
--
e9
cso30:c:EntityBiologicalCompartment
cso30:i:CC_Cytoplasm
--
--
--
csml-variable:Double
m9
0
infinite
0
--
NF-AT {activated}
--
e90
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m94
10
infinite
0
TRANSPATH | MO000017212 |
--
csml-variable:Double
m95
0
infinite
0
--
CBM complex: PKCtheta {p}
--
e92
cso30:c:Complex
cso30:i:CC_Cytosol
--
csml-variable:Double
m96
0
infinite
0
--
PMA: TCR
--
e93
cso30:c:Complex
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
csml-variable:Double
m97
0
infinite
0
--
PLCbeta {activated}
--
e94
cso30:c:Protein
cso30:i:CC_CellComponent
--
csml-variable:Double
m98
10
infinite
0
TRANSPATH | MO000000133 |
--
PLCgamma2 {activated}
--
e95
cso30:c:Protein
cso30:i:CC_CellComponent
--
--
csml-variable:Double
m99
10
infinite
0
InterPro | IPR001452 |
TRANSPATH | MO000017704 |
--
CD25
--
e96
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m100
0
infinite
0
--
Bcl-xL
--
e97
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
csml-variable:Double
m101
0
infinite
0
--
cytokines
--
e98
cso30:c:mRNA
cso30:i:CC_Nucleoplasm
--
--
csml-variable:Double
m102
0
infinite
0
--
chemokines
--
e99
cso30:c:mRNA
cso30:i:CC_Nucleolus
--
--
csml-variable:Double
m103
0
infinite
0
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c1 : 1
stoichiometry:c2 : 1
stoichiometry:c3 : 1
m16*m3962*0.1
nodelay
--
0
PMID: 17046325 Following ligand stimulation, TLRs associate with adaptor proteins such as myeloid differentiation primary response gene (MyD)88 through interaction between the individual Toll and interleukin-1 receptor (TIR) domains.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c27 : 1
stoichiometry:c28 : 1
stoichiometry:c29 : 1
m1572*m27*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c303 : 1
stoichiometry:c313 : 1
stoichiometry:c293 : 1
m19*m44*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c319 : 1
stoichiometry:c320 : 1
m90*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKCtheta co-operates with the CBM complex to culminate in NF-kappaB activation.
p41
p102
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c322 : 1
stoichiometry:c178 : 1
stoichiometry:c179 : 1
stoichiometry:c323 : 1
m96*m111*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p11
p11
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c31 : 1
stoichiometry:c32 : 1
stoichiometry:c33 : 1
m31*m19940*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p12
p12
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c34 : 1
stoichiometry:c35 : 1
stoichiometry:c36 : 1
m31*m19823*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p13
p13
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_ExternalSideOfPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c37 : 1
stoichiometry:c38 : 1
stoichiometry:c39 : 1
m19828*m22*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p14
p14
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c40 : 1
stoichiometry:c41 : 1
stoichiometry:c42 : 1
m3966*m6485*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c43 : 1
stoichiometry:c44 : 1
stoichiometry:c45 : 1
m1572*m35*0.1
nodelay
--
0
PMID: 17046325 Following TLR5 stimulation, MyD88 but not TIRAP is recruited into the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c46 : 1
stoichiometry:c48 : 1
stoichiometry:c49 : 1
m1572*m32*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c47 : 1
stoichiometry:c50 : 1
stoichiometry:c51 : 1
m1572*m33*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c52 : 1
stoichiometry:c53 : 1
stoichiometry:c54 : 1
m34*m1572*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p19
p19
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c56 : 1
stoichiometry:c59 : 1
stoichiometry:c61 : 1
stoichiometry:c65 : 1
stoichiometry:c68 : 1
stoichiometry:c71 : 1
stoichiometry:c73 : 1
stoichiometry:c77 : 1
m184*m17258*m183*m979*m980*m1872*m38*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p2
p2
cso30:i:ME_Binding
cso30:i:CC_PlasmaMembrane_IntegralToPlasmaMembrane_
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c4 : 1
stoichiometry:c6 : 1
stoichiometry:c5 : 1
m1572*m17*0.1
nodelay
--
0
PMID: 17046325 Following ligand stimulation, TLRs associate with adaptor proteins such as myeloid differentiation primary response gene (MyD)88 through interaction between the individual Toll and interleukin-1 receptor (TIR) domains.
p20
p20
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c55 : 1
stoichiometry:c58 : 1
stoichiometry:c62 : 1
stoichiometry:c64 : 1
stoichiometry:c67 : 1
stoichiometry:c70 : 1
stoichiometry:c74 : 1
stoichiometry:c76 : 1
m184*m17258*m183*m979*m980*m1872*m39*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p21
p21
cso30:i:ME_Binding
cso30:i:CC_EndosomeLumen
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c57 : 1
stoichiometry:c60 : 1
stoichiometry:c63 : 1
stoichiometry:c66 : 1
stoichiometry:c69 : 1
stoichiometry:c72 : 1
stoichiometry:c75 : 1
stoichiometry:c78 : 1
m184*m17258*m183*m979*m980*m1872*m40*0.1
nodelay
--
0
PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
p22
p22
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c79 : 1
stoichiometry:c80 : 1
stoichiometry:c81 : 1
m155666*m3961*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c84 : 1
stoichiometry:c85 : 1
stoichiometry:c86 : 1
m44*m19005*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c83 : 1
stoichiometry:c88 : 1
stoichiometry:c82 : 1
m44*m6810*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c89 : 1
stoichiometry:c90 : 1
stoichiometry:c91 : 1
m45*m1572*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c87 : 1
stoichiometry:c92 : 1
stoichiometry:c93 : 1
m46*m18998*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c94 : 1
stoichiometry:c95 : 1
stoichiometry:c96 : 1
m15*m48*0.1
nodelay
--
0
PMID: 17046325 However, after TLR4 stimulation, the TIR domain-containing adaptor protein inducing interferon ¦Â (TRIF)-related adaptor molecule (TRAM)?TRIF?RIP1 (receptor-interacting protein 1) signaling pathway is activated in addition to the TIRAP?MyD88 signaling pathway.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c97 : 1
stoichiometry:c98 : 1
stoichiometry:c99 : 1
m3965*m65*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c100 : 1
stoichiometry:c101 : 1
stoichiometry:c102 : 1
m63*m18998*0.1
nodelay
--
0
PMID: 17046325 TLR3 signaling, only TRIF and RIP1 are recruited. The TRAM?TRIF?RIP1 signaling pathway is MyD88-independent but IRAK-4-dependent.
p3
p3
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c7 : 1
stoichiometry:c8 : 1
stoichiometry:c14 : 1
stoichiometry:c321 : 1
m3964*m3963*m108*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c103 : 1
stoichiometry:c104 : 1
stoichiometry:c105 : 1
m15*m64*0.1
nodelay
--
0
PMID: 17046325 TLR3 signaling, only TRIF and RIP1 are recruited. The TRAM?TRIF?RIP1 signaling pathway is MyD88-independent but IRAK-4-dependent.
p31
p31
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c106 : 1
stoichiometry:c107 : 1
stoichiometry:c108 : 1
stoichiometry:c109 : 1
stoichiometry:c205 : 1
stoichiometry:c110 : 1
m184*m17258*m979*m183*m18*0.1
nodelay
--
0
PMID: 17046325 IRAK-4, IRAK-1, IRF5 and TRAF6 are then recruited to the TLRs, which induces the association of IRAK-4 and MyD88 through their death domains. PMID: 17046325 Following TLR7, TLR8 and/or TLR9 stimulation, a cytoplasmic signaling complex consisting of MyD88, IRAK-1, interferon regulatory factor (IRF)-5, IRF-7, TNF receptor-associated factor (TRAF)3, TRAF6 and IRAK-4 is formed.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c111 : 1
stoichiometry:c112 : 1
m67*0.1
nodelay
--
0
PMID: 17046325 RAK-1 is phosphorylated by IRAK-4 and dissociates from the receptor together with TRAF6.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c113 : 1
stoichiometry:c114 : 1
stoichiometry:c115 : 1
m70*0.1
nodelay
--
0
PMID: 17046325 RAK-1 is phosphorylated by IRAK-4 and dissociates from the receptor together with TRAF6.
p34
p34
cso30:i:ME_Binding
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c116 : 1
stoichiometry:c117 : 1
stoichiometry:c118 : 1
stoichiometry:c119 : 1
stoichiometry:c120 : 1
stoichiometry:c121 : 1
stoichiometry:c122 : 1
m68*m1573*m1583*m6433*m6443*m14*0.1
nodelay
--
0
PMID: 17046325 The released TRAF6 interacts with transforming growth factor (TGF)-beta-activated kinase (TAK)1, and TRAF6?TAK1 forms a large complex with E2 ubiquitin-conjugating enzyme (Ubc)13, ubiquitin-conjugating enzyme E2 variant 1 isoform A (Uev1A) and TAK1-binding protein (TAB)1?TAB2.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c123 : 1
stoichiometry:c124 : 1
m72*0.1
nodelay
--
0
PMID: 17046325 The released TRAF6 interacts with transforming growth factor (TGF)-beta-activated kinase (TAK)1, and TRAF6?TAK1 forms a large complex with E2 ubiquitin-conjugating enzyme (Ubc)13, ubiquitin-conjugating enzyme E2 variant 1 isoform A (Uev1A) and TAK1-binding protein (TAB)1?TAB2. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c125 : 1
stoichiometry:c126 : 1
stoichiometry:c127 : 1
m73*m5*0.1
nodelay
--
0
PMID: 17046325 Activated TAK1 phosphorylates and activates the IKK complex, consisting of IKK1, IKK2 and NEMO. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c130 : 1
stoichiometry:c128 : 1
stoichiometry:c129 : 1
m74*m107*0.1
nodelay
--
0
PMID: 17046325 The IKK complex induces IkappaB phosphorylation, which results in I¦ÊB ubiquitination and degradation. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p38
p38
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c131 : 1
stoichiometry:c136 : 1
stoichiometry:c132 : 1
m69*m73*0.1
nodelay
--
0
PMID: 17046325 Activated TAK1 also induces the activation of various stress kinases, including c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK).
p39
p39
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c133 : 1
stoichiometry:c135 : 1
stoichiometry:c134 : 1
m21*m73*0.1
nodelay
--
0
PMID: 17046325 Activated TAK1 also induces the activation of various stress kinases, including c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK).
p4
p4
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c10 : 1
stoichiometry:c11 : 1
stoichiometry:c16 : 1
stoichiometry:c9 : 1
m3964*m3987*m109*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c137 : 1
stoichiometry:c138 : 1
m110*0.1
nodelay
--
0
PMID: 17046325 The IKK complex induces IkappaB phosphorylation, which results in I¦ÊB ubiquitination and degradation. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p41
p41
cso30:i:ME_ProteasomeDegradation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c139 : 1
stoichiometry:c140 : 1
stoichiometry:c141 : 1
m111*0.1
nodelay
--
0
PMID: 17046325 The IKK complex induces IkappaB phosphorylation, which results in I¦ÊB ubiquitination and degradation. PMID: 17046325 IkappaB degradation liberates NF-kappaB and enables it to translocate into the nucleus where it can induce target gene expression. PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c142 : 1
stoichiometry:c143 : 1
m6*0.1
nodelay
--
0
PMID: 17046325 IkappaB degradation liberates NF-kappaB and enables it to translocate into the nucleus where it can induce target gene expression.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c144 : 1
stoichiometry:c145 : 1
m67*0.1
nodelay
--
0
PMID: 17046325 Recently, it was revealed that IRF-5 interacts with, and is activated by, MyD88 and TRAF6, although it is unclear how IRAK-1, IRAK-4 and IRF-5 regulate TRAF6 dissociation from the receptor complex.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c147 : 1
stoichiometry:c149 : 1
stoichiometry:c148 : 1
m82*m85*0.1
nodelay
--
0
PMID: 17046325 In acquired immunity, the TCR recognizes a specific antigen?MHC complex on APCs. PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76.
p45
p45
cso30:i:ME_Phosphorylation
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c146 : 1
stoichiometry:c151 : 1
stoichiometry:c150 : 1
m84*m123*0.1
nodelay
--
0
PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c152 : 1
stoichiometry:c153 : 1
stoichiometry:c154 : 1
m2529*m86*0.1
nodelay
--
0
PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c159 : 1
stoichiometry:c155 : 1
stoichiometry:c156 : 1
m87*m88*0.1
nodelay
--
0
PMID: 17046325 TCR engagement results in the phosphorylation of TCR-associated CD3zeta chains by Lck and the recruitment of ZAP-70 to the phosphorylated CD3zeta chains, inducing phosphorylation of the adaptor proteins LAT and SLP-76. PMID: 17046325 PLC-gamma1 is recruited to the phosphorylated LAT?SLP-76 and generates Ins(1,4,5)P3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c157 : 1
stoichiometry:c158 : 1
stoichiometry:c160 : 1
m89*m2395*0.1
nodelay
--
0
PMID: 17046325 PLC-gamma1 is recruited to the phosphorylated LAT?SLP-76 and generates Ins(1,4,5)P3.
p49
p49
cso30:i:ME_UnknownProduction
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c161 : 1
stoichiometry:c162 : 1
m90*0.1
nodelay
--
0
PMID: 17046325 PLC-gamma1 is recruited to the phosphorylated LAT?SLP-76 and generates Ins(1,4,5)P3.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c13 : 1
stoichiometry:c17 : 1
stoichiometry:c204 : 1
m30*m100*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
p50
p50
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c163 : 1
stoichiometry:c168 : 1
stoichiometry:c186 : 1
stoichiometry:c187 : 1
stoichiometry:c164 : 1
m2259*m92*m2019*m2395*0.1
nodelay
--
0
PMID: 17046325 IRAK-4 affects only the phosphorylation of PKCtheta but not of CD3zeta, ZAP-70 or LAT. PMID: 17046325, 15802604 Although 3-phosphoinositide-dependent protein kinase (PDK)1 is responsible for activating PKCtheta and subsequent NF-kappaB activation after TCR stimulation , the association of IRAK-4 with PKCtheta or PDK1 was not observed. PMID: 17046325 It can be assumed that PKCbeta activation in B cells requires only PLC-gamma2 activation, whereas PKCtheta activation in T cells requires both PLC-gamma1 and IRAK-4.
p51
p51
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c165 : 1
stoichiometry:c166 : 1
stoichiometry:c167 : 1
m87*m17258*0.1
nodelay
--
0
PMID: 17046325 IRAK-4 constitutively associates with ZAP-70, and the assembled ZAP-70?IRAK-4 complex can be recruited to the TCR vicinity following stimulation.
p52
p52
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c169 : 1
stoichiometry:c171 : 1
stoichiometry:c170 : 1
m1676*m90*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKCtheta co-operates with the CBM complex to culminate in NF-kappaB activation.
p53
p53
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c172 : 1
stoichiometry:c174 : 1
stoichiometry:c232 : 1
stoichiometry:c233 : 1
stoichiometry:c234 : 1
stoichiometry:c173 : 1
m2078*m93*m104*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKCtheta co-operates with the CBM complex to culminate in NF-kappaB activation. PMID: 17046325 TCR signals could then have diversified into Ca2+-independent NF-kappaB activation and Ca2+-dependent NF-AT activation. PMID: 17046325 Cyclosporine A and FK506 specifically inhibit NF-AT activation in TCR signaling, and have been used for successful organ transplantation.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c175 : 1
stoichiometry:c176 : 1
stoichiometry:c177 : 1
m91*m95*0.1
nodelay
--
0
PMID: 17046325 LAT?SLP-76?PLCgamma1 induces Ca2+ mobilization, the activation of calcineurin and, finally, NF-AT activation (iv), whereas PKC¦È co-operates with the CBM complex to culminate in NF-kappaB activation.
p56
p56
cso30:i:ME_Binding
cso30:i:CC_Extracellular
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c180 : 1
stoichiometry:c181 : 1
stoichiometry:c182 : 1
m2534*m117377*0.1
nodelay
--
0
PMID:17046325, 16574867, 11861617 Functional analyses demonstrated that IRAK-4-deficient T cells failed to respond to TCR stimulation but were able to respond to phorbol 12-myristate 13-acetate (PMA) stimulation [25] that directly activates protein kinase C (PKC)theta.
p57
p57
cso30:i:ME_Phosphorylation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c183 : 1
stoichiometry:c184 : 1
stoichiometry:c185 : 1
m97*m2259*0.1
nodelay
--
0
PMID:17046325, 16574867, 11861617 Functional analyses demonstrated that IRAK-4-deficient T cells failed to respond to TCR stimulation but were able to respond to phorbol 12-myristate 13-acetate (PMA) stimulation [25] that directly activates protein kinase C (PKC)theta.
p58
p58
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c188 : 1
stoichiometry:c189 : 1
m120*0.1
nodelay
--
0
PMID: 17046325 It can be assumed that PKCbeta activation in B cells requires only PLC-gamma2 activation, whereas PKCtheta activation in T cells requires both PLC-gamma1 and IRAK-4.
p59
p59
cso30:i:ME_UnknownActivation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c190 : 1
stoichiometry:c206 : 1
stoichiometry:c191 : 1
m2464*m98*0.1
nodelay
--
0
PMID: 17046325 It can be assumed that PKCbeta activation in B cells requires only PLC-gamma2 activation, whereas PKCtheta activation in T cells requires both PLC-gamma1 and IRAK-4.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c12 : 1
stoichiometry:c15 : 1
stoichiometry:c18 : 1
m30*m101*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c195 : 1
stoichiometry:c203 : 1
stoichiometry:c193 : 1
m100*m29*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c194 : 1
stoichiometry:c202 : 1
stoichiometry:c192 : 1
m101*m29*0.1
nodelay
--
0
PMID: 17046325, 16761317 Indeed, TLR2 induces co-stimulation in activated CD8+ T cells for proliferation and survival through the enhanced expression of CD25 and Bcl-xL.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c196 : 1
stoichiometry:c200 : 1
m36*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p63
p63
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c197 : 1
stoichiometry:c221 : 1
stoichiometry:c201 : 1
m94230*m37*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p64
p64
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c198 : 1
stoichiometry:c222 : 1
stoichiometry:c199 : 1
m93423*m41*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p65
p65
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c207 : 1
stoichiometry:c219 : 1
stoichiometry:c217 : 1
m93423*m37*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p66
p66
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c208 : 1
stoichiometry:c223 : 1
stoichiometry:c218 : 1
m93423*m42*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c209 : 1
stoichiometry:c220 : 1
stoichiometry:c215 : 1
m36*m37*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c210 : 1
stoichiometry:c216 : 1
m36*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
p69
p69
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c211 : 1
stoichiometry:c225 : 1
stoichiometry:c213 : 1
m94230*m41*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c20 : 1
stoichiometry:c21 : 1
stoichiometry:c24 : 1
m6810*m26*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
p70
p70
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c212 : 1
stoichiometry:c224 : 1
stoichiometry:c214 : 1
m94230*m42*0.1
nodelay
--
0
PMID: 17046325, 16034093 In the absence of antigen-presenting cells (APCs), flagellin (a TLR5 ligand) and R-848 (a TLR7 and/or TLR8 ligand) are synergized by suboptimal TCR-dependent or TCR-independent stimulation to enhance the proliferation and production of IFN-gamma, IL-8 and IL-10 by human CD4+ T cells.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c228 : 1
stoichiometry:c230 : 1
stoichiometry:c226 : 1
m102*m67*0.1
nodelay
--
0
PMID: 17046325 Collectively, these studies demonstrated that some components from invading microorganisms stimulate TLRs on T cells directly, and enhance proliferation, cytokine and chemokine productions, and effector function.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c229 : 1
stoichiometry:c231 : 1
stoichiometry:c227 : 1
m103*m67*0.1
nodelay
--
0
PMID: 17046325 Collectively, these studies demonstrated that some components from invading microorganisms stimulate TLRs on T cells directly, and enhance proliferation, cytokine and chemokine productions, and effector function.
p73
p73
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c238 : 1
stoichiometry:c240 : 1
stoichiometry:c236 : 1
m93423*m44*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p74
p74
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c237 : 1
stoichiometry:c239 : 1
stoichiometry:c235 : 1
m93423*m66*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p75
p75
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c241 : 1
stoichiometry:c242 : 1
stoichiometry:c243 : 1
m43*m93423*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c249 : 1
stoichiometry:c266 : 1
stoichiometry:c244 : 1
m83*m43*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c250 : 1
stoichiometry:c268 : 1
stoichiometry:c245 : 1
m83*m41*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c251 : 1
stoichiometry:c270 : 1
stoichiometry:c246 : 1
m83*m42*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c252 : 1
stoichiometry:c272 : 1
stoichiometry:c247 : 1
m83*m66*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c19 : 1
stoichiometry:c22 : 1
stoichiometry:c23 : 1
m6810*m25*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c253 : 1
stoichiometry:c264 : 1
stoichiometry:c248 : 1
m83*m44*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p81
p81
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c254 : 1
stoichiometry:c267 : 1
stoichiometry:c259 : 1
m93217*m43*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p82
p82
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c255 : 1
stoichiometry:c269 : 1
stoichiometry:c260 : 1
m93217*m41*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p83
p83
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c256 : 1
stoichiometry:c271 : 1
stoichiometry:c261 : 1
m93217*m42*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p84
p84
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c257 : 1
stoichiometry:c273 : 1
stoichiometry:c262 : 1
m93217*m66*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p85
p85
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c258 : 1
stoichiometry:c265 : 1
stoichiometry:c263 : 1
m93217*m44*0.1
nodelay
--
0
PMID: 17046325, 15229469 Only five TLRs ? TLR3, TLR4, TLR7, TLR8 and TLR9 ? produce IFNalpha, IFNbeta and IFNgamma as innate immune responses.
p86
p86
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c279 : 1
stoichiometry:c304 : 1
stoichiometry:c274 : 1
m93309*m30*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p87
p87
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c280 : 1
stoichiometry:c307 : 1
stoichiometry:c275 : 1
m93309*m29*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p88
p88
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c283 : 1
stoichiometry:c315 : 1
stoichiometry:c277 : 1
m93309*m44*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p89
p89
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c281 : 1
stoichiometry:c310 : 1
stoichiometry:c276 : 1
m93309*m66*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c25 : 1
stoichiometry:c30 : 1
stoichiometry:c26 : 1
m1572*m28*0.1
nodelay
--
0
PMID: 17046325 After TLR1, TLR2 and/or TLR6 stimulation, TIR domain-containing adaptor protein (TIRAP) and MyD88 are recruited to TLRs.
p90
p90
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c282 : 1
stoichiometry:c318 : 1
stoichiometry:c278 : 1
m93309*m43*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p91
p91
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c294 : 1
stoichiometry:c305 : 1
stoichiometry:c284 : 1
m93248*m30*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p92
p92
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c295 : 1
stoichiometry:c308 : 1
stoichiometry:c285 : 1
m93248*m29*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p93
p93
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c296 : 1
stoichiometry:c311 : 1
stoichiometry:c286 : 1
m93248*m66*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p94
p94
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c297 : 1
stoichiometry:c316 : 1
stoichiometry:c287 : 1
m93248*m43*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
p95
p95
cso30:i:ME_Translation
cso30:i:CC_Cytosol
--
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c298 : 1
stoichiometry:c314 : 1
stoichiometry:c288 : 1
m93248*m44*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c299 : 1
stoichiometry:c306 : 1
stoichiometry:c289 : 1
m19*m30*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c300 : 1
stoichiometry:c309 : 1
stoichiometry:c290 : 1
m19*m29*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c301 : 1
stoichiometry:c312 : 1
stoichiometry:c291 : 1
m19*m66*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
--
and
mass
coefficient1:0.1
coefficient2:1.0
stoichiometry:c302 : 1
stoichiometry:c317 : 1
stoichiometry:c292 : 1
m19*m43*0.1
nodelay
--
0
PMID: 17046325 In vitro, these cells from IRAK-4-deficient mice failed to produce pro-inflammatory cytokines such as IL-1, IL-6 and tumor necrosis factor (TNF) in response to various ligands for TLR2, TLR3, TLR4 and TLR9 including lipopolysaccharide (LPS), polyinosinic:polycytidylic acid (polyI:C), and oligodeoxynucleotides (ODNs) that contain unmethylated CpG motifs (CpG-ODNs).
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:InputInhibitor
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputAssociation
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:OutputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--
cso30:c:InputProcess
threshold
--
0
1,
--